Reprexain

Quick links to important sections

Reprexain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reprexain

Defining Reprexain: A Dual-Action Analgesic

Property Description
Active Ingredients Hydrocodone bitartrate, Ibuprofen
Form Film-coated tablet
Pharmacological Class Narcotic analgesic combination, NSAID
General Purpose Relief of moderate to severe pain
Origin Semisynthetic (Hydrocodone) and Synthetic (Ibuprofen)

Reprexain is a prescription-only medication classified as a narcotic analgesic combination, utilizing two distinct agents to manage pain. It is supplied as a fixed combination product where the active ingredients are integrated into a single film-coated tablet designed for oral administration. The components are a blend of origins: Hydrocodone bitartrate is a semisynthetic opioid analgesic, while Ibuprofen is a synthetic nonsteroidal anti-inflammatory drug (NSAID). Other common brand names containing this identical formulation include Vicoprofen and Ibudone.

This formulation strategically combines an agent that acts on the central nervous system with one that works peripherally. This combination is utilized for its analgesic properties and is used for the general relief of discomfort, particularly in scenarios where non-opioid medications have proven insufficient.

Composition: Hydrocodone Bitartrate and Ibuprofen

The core of Reprexain’s composition consists of the active ingredients: Hydrocodone bitartrate and Ibuprofen. Hydrocodone bitartrate functions primarily by modulating pain signals in the central nervous system, whereas Ibuprofen concurrently exerts its effect by inhibiting the cyclooxygenase (COX) enzyme activity, thereby reducing the production of prostaglandins, key chemical mediators of inflammation and localized pain.

This precise co-formulation ensures that both the analgesic component and the anti-inflammatory component are delivered simultaneously within a solid, oral fixed-dose combination. Combining an opioid with an NSAID is a strategy to manage pain through complementary mechanisms. The inclusion of Ibuprofen in this combination is a key differentiating factor, providing anti-inflammatory action that is absent in common hydrocodone/acetaminophen products.

The Primary Benefit of the Combination

The inherent benefit of this product is its capacity for an enhanced analgesic effect achieved through the dual mechanism of action. By simultaneously addressing the sensation of pain centrally and controlling the inflammation that contributes to pain peripherally, the formulation provides a more complete level of relief than either Hydrocodone or Ibuprofen could typically offer alone. The design of the fixed combination tablet ensures consistency in the co-administration of the opioid analgesic and the NSAID.

What side effects are possible with Reprexain?

Possible Side Effects and Safety Information

The safety profile of Reprexain reflects the risks associated with its dual components: the opioid analgesic, hydrocodone, and the nonsteroidal anti-inflammatory drug (NSAID), ibuprofen. The regulatory documentation classifies adverse effects by frequency and system involvement.

Documented Adverse Reactions

Reactions officially listed as Common (reported in ge 1% of patients) primarily include gastrointestinal effects such as nausea, vomiting, constipation, and dyspepsia. Central nervous system effects commonly observed are dizziness, somnolence (drowsiness), and headache. Uncommon reactions documented include insomnia, nervousness, diarrhea, and rash.

Serious Adverse Reactions and Systemic Risks

Official labeling contains warnings regarding serious risks. The NSAID component is associated with a risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. The risk of these events may occur early in treatment and increase with the duration of use. This component also poses a risk of serious gastrointestinal events, such as bleeding, ulceration, and perforation, which may occur at any time without warning symptoms.

Separately, the hydrocodone component carries the risk of life-threatening respiratory depression, particularly when used with other central nervous system depressants, and the potential for developing physical dependence.

Population and Contextual Safety

Specific safety considerations are noted for patient populations. Older adults have a documented increased risk of serious gastrointestinal and renal toxicity. Use is generally restricted or contraindicated in cases of severe renal or hepatic failure. The safety and effectiveness of this combination are not established in the pediatric population.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of the hydrocodone bitartrate and ibuprofen combination may present with symptoms resulting from both the opioid and the NSAID components. The most severe manifestation of hydrocodone overexposure is life-threatening respiratory depression, which can lead to coma and may be fatal. Other documented signs include profound sedation, excessive drowsiness, and pinpoint pupils (miosis). Conversely, the ibuprofen component may lead to signs such as nausea, vomiting, epigastric pain, and the potential for seizures or gastrointestinal bleeding.

Required Emergency Actions

Immediate medical attention is mandatory for any suspected overdose. Regulatory documents mandate that patients seek emergency medical attention or call a Poison Help line right away if too much is taken. Accidental ingestion of even one dose, especially by a child, is explicitly classified as a medical emergency due to the risk of fatal outcome. Older adults or those with pre-existing breathing disorders may be at higher risk for serious respiratory problems during an overdose.

Management and Antidote

The official regulatory approach to overdose involves ensuring a patent airway and adequate respiratory exchange. Naloxone hydrochloride is the specific antidote for reversing the hydrocodone-induced respiratory depression. For all other effects, management is symptomatic and supportive, which may include monitoring of vital signs, activated charcoal, or gastric emptying procedures to reduce drug absorption.

Therapeutic Uses of Reprexain

What Reprexain Treats: Main Uses and Benefits

Reprexain is considered relevant for easing symptoms related to the relief of acute pain.


This medication is commonly used to help with symptoms related to intense somatic and nociceptive pain associated with acute injury or surgical procedures, such as trauma or dental extractions. It provides symptomatic support during these demanding acute pain states and is applied when supportive symptom management beyond typical non-opioid assistance is deemed appropriate. The medication supports the management of both the physical discomfort and the inflammatory components of the symptoms, contributing to easing the overall symptom load during short-term episodes. This makes the medication relevant for conditions characterized by periods of heightened symptoms that interfere with daily functioning.

The combination is applied in situations where painful symptoms are exacerbated by localized inflammation, including swelling and tenderness. It is intended for short-term assistance in symptom management, supports patients during difficult episodes by easing distress, and assists with managing symptoms that interfere with daily comfort during periods where symptoms become more noticeable.


Quick Fact: Supportive Relief for Intense Musculoskeletal Symptoms

Common Therapeutic Uses: Reprexain is commonly used to help with acute, painful episodes following trauma, post-surgical recovery, and instances of severe musculoskeletal discomfort.

Regulatory References

  1. REPREXAIN (hydrocodone bitartrate, ibuprofen) tablet, film coated - DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Reprexain

This section outlines the population eligibility and non-eligibility rules for Reprexain (hydrocodone bitartrate/ibuprofen), based strictly on government-approved labeling.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents ge 16 years of age.
Populations for whom use is not recommended Patients with advanced renal disease; use in breastfeeding mothers is generally not recommended.
Populations for whom use is contraindicated Patients with known hypersensitivity to hydrocodone, ibuprofen, aspirin, or any other NSAID. Use for peri-operative pain in CABG surgery.
Age-related eligibility rules Safety and effectiveness not established in children younger than 16 years of age.
Pregnancy and lactation eligibility status Contraindicated at 30 weeks gestation and later. Use avoided from 20 weeks gestation onward.
Eligibility-related restrictions Use requires caution in elderly or debilitated patients and those with a history of GI bleeding or ulceration.

Official eligibility statements:

  • Contraindicated for individuals with known hypersensitivity to the drug components or any other NSAID, including a history of asthma or allergic-type reactions to aspirin.
  • Prohibited for treating pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with significant respiratory depression.
  • Use not established in children younger than 16 years of age.
  • Requires caution in elderly patients and those with pre-existing heart failure or hypertension.

The regulatory documentation defines eligibility through mandatory restrictions that reflect the risks of its hydrocodone (opioid) and ibuprofen (NSAID) components. Specific populations, such as those with NSAID allergies or advanced renal disease, are officially excluded or subject to strict limitations, confirming the medicine is established for use in acute pain management for adults and adolescents ge 16 years of age under defined conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Reprexain, a combination of hydrocodone and ibuprofen, is structured around high-risk pharmacodynamic and pharmacokinetic interactions.

Contraindicated Combinations

Entity Official Outcome/Restriction
CABG Surgery Setting The medicine is formally contraindicated for peri-operative pain relief in the setting of Coronary Artery Bypass Graft surgery.

Documented Interactions

Pharmacodynamic Interactions: Concomitant use with CNS depressants (including alcohol, benzodiazepines, muscle relaxants, and other opioids) may result in profound sedation, respiratory depression, coma, and death. The ibuprofen component may diminish the therapeutic effect of diuretics and certain antihypertensive agents. Use with anticoagulants (e.g., Warfarin) carries a synergistic risk of serious gastrointestinal bleeding. Co-administration with Aspirin (antiplatelet use) is not generally recommended.

Pharmacokinetic Interactions: Co-administration with CYP3A4 inhibitors may cause an increase in hydrocodone plasma concentrations. Conversely, CYP3A4 inducers may cause a decrease in these concentrations. The use of Monoamine Oxidase Inhibitors (MAOIs) is not recommended within 14 days of stopping MAOI treatment due to risk of intensified opioid effects.

Mechanism of Action

Reprexain is a selective inhibitor of the cyclin-dependent kinase 4 and 6 (Cdk4/6) pathway . This binding action prevents the phosphorylation of the retinoblastoma protein ( pRb).

The non-phosphorylated pRb remains functionally bound to the E2F transcription factors, thereby inhibiting the gene transcription necessary for cell division. This block ultimately prevents the malignant cell from transitioning from the G1 phase into the S phase of the cell cycle.

The resulting G1 arrest leads to a reduction in the cellular proliferation rate of malignant osteoclasts. This intracellular process specifically modulates the osteoclast-mediated bone resorption cycle.

Dosage and Administration Information

How to Use Reprexain: Administration Guidelines

Reprexain (Hydrocodone Bitartrate and Ibuprofen) is administered based on a protocol governing its short-term use for acute pain management.


Administration Protocol

Instruction Detail
Route and Form The medicine is for oral administration as a fixed-combination, film-coated tablet.
Standard Dosing The single dose is one tablet, containing 7.5 mg of hydrocodone bitartrate and 200 mg of ibuprofen.
Frequency and Limit Dosing is permitted every 4 to 6 hours, as needed. The total dose administered must not exceed 5 tablets in any 24-hour period.
Duration of Use The overall administration is short-term, adhering to the principle of using the lowest effective dose for the shortest duration necessary for acute relief.

Procedural Constraints and Timing

The administration schedule is defined by specific procedural rules. Reprexain is classified as an as-needed (PRN) medication with a 4-hour minimum interval between doses. If a dose is missed, the protocol is to take only the next dose at the usual scheduled time without doubling the dose.

A constraint upon administration is the prohibition of concomitant use; the patient must not take any other nonsteroidal anti-inflammatory drugs (NSAIDs) while undergoing Reprexain therapy. Furthermore, if the medicine has been taken on a regular schedule, discontinuation involves consultation with a healthcare provider. Dose adjustments for specific populations are not explicitly detailed in the combination product's immediate information.

This structure ensures that the administration of the fixed-dose combination follows the dose limits and scheduling defined for the product.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research has explored the use of this compound, which combines an opioid analgesic and an NSAID, in the context of severe inflammatory conditions. Studies specifically evaluated whether the compound was associated with changes in patient-reported symptoms and other measures of joint pain.


Clinical Trial Designs

Investigators have conducted several placebo-controlled trials and long-term observational studies focusing on the compound's components. Research assessed inflammatory marker levels over time in studies utilizing the compound. Trial designs consistently included assessment of tolerability and the incidence of adverse events as a key focus.


Specific Research Areas

Long-Term Evaluation

Specific research evaluated the compound in populations that included individuals presenting with mild liver impairment. The investigation focused on the incidence of adverse events and the potential necessity for dose modification in this group. The compound was studied alongside research focusing on older treatments, providing comparative context for the therapeutic approach.

Dosing and Combination

  • Absorption: Some studies evaluated differences in drug absorption when the compound was administered with food compared to without food.
  • Combination: Investigators also examined mobility outcomes when the compound was administered alongside physical therapy. The research was designed to examine patient-reported outcomes (PROs) in monotherapy versus combination therapy groups. Researchers have explored whether the compound affects indices related to structural changes in joints over time.

Note on Research Overview: This overview is purely descriptive of the research conducted and does not constitute medical advice, recommendations, or interpretations regarding treatment suitability.

Frequently Asked Questions (FAQ)

Common questions about Reprexain (FAQ)


Q: If I miss a dose of Reprexain, what are the general guidelines?

A: Reprexain is an as-needed (PRN) medication. If a dose is missed, official administration instructions advise taking only the next dose at the usual time that the medicine would be needed. Regulatory instructions state that the missed dose should not be doubled or taken with the next scheduled dose, as this could exceed official maximum limits.


Q: Are there certain foods or drinks that should be avoided while using Reprexain?

A: Regulatory documents describe a severe interaction risk when Reprexain is used concomitantly with alcohol, which can lead to profound sedation and respiratory depression. Although there are no specific foods that are prohibited, official documents recommend informing a healthcare provider about all non-prescription medications and herbal products you are taking due to potential interactions.


Q: What happens if I stop taking Reprexain suddenly?

A: Official guidelines state that if Reprexain has been taken on a regular schedule, discontinuation requires consultation with a healthcare provider. Sudden cessation may be associated with withdrawal symptoms or rebound pain, as the opioid component has the potential to cause physical dependence.


Q: How should Reprexain be stored to keep it effective?

A: Official documentation specifies that Reprexain should be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), in a tight, light-resistant container to help maintain its stability and effectiveness. Due to the presence of an opioid, the medication must also be stored in a secure location and kept out of the sight and reach of children to prevent accidental ingestion and serious harm.


Q: Is Reprexain a strong medicine or is it considered mild?

A: According to official classification, Reprexain is a narcotic analgesic combination approved for the relief of moderate to severe pain. This classification indicates that the medicine is used for the management of pain, particularly in situations where an opioid is considered appropriate.


Q: How quickly should I feel Reprexain starting to work?

A: Official pharmacokinetic studies indicate that the maximum concentration of the hydrocodone component in the blood is typically reached in approximately 1.7 hours after a dose. The ibuprofen component reaches its peak around 1.8 hours. This timeframe generally suggests when the medication’s peak effects may be expected.


Q: Can Reprexain affect my mood or energy levels?

A: Yes, official labeling documents list several effects on the central nervous system. Common documented effects include dizziness, somnolence (drowsiness), and headache. Other documented effects can include mood changes, anxiety, and nervousness.


Q: Is it true that Reprexain can interact with certain common vitamins or supplements?

A: Official regulatory information advises informing a healthcare provider about all prescription and nonprescription medications, vitamins, and herbal products. Specific herbal products like St. John's wort are noted to potentially interact with the hydrocodone component. These interactions can change how the medicine works in the body.


Q: Are there any long-term effects of taking Reprexain that I should know about?

A: Reprexain is officially approved only for short-term use for acute pain. The risks of its components—such as cardiovascular events and gastrointestinal bleeding—may increase with the duration of use. The long-term use of the opioid component is also associated with a potential decrease in sex hormone levels.


Q: Can taking Reprexain cause weight gain or weight loss?

A: Official safety warnings for the ibuprofen component mention the risk of fluid retention and the onset or worsening of heart failure. Unexplained or sudden weight gain and swelling are listed as signs of heart failure, which is a serious adverse reaction, but generalized weight gain or loss is not listed as a common side effect.


Q: Why do some people say they need to take a break from Reprexain?

A: Official guidelines emphasize limiting Reprexain to the shortest duration necessary for acute pain management. This short-term use strategy helps to reduce specific risks, including the potential for developing physical dependence and tolerance to the opioid component. These risks are common factors that inform decisions about treatment duration.


Q: Is it normal to have mild headaches when starting Reprexain?

A: Yes, headache is officially listed as a common adverse reaction associated with Reprexain. This means it was reported in at least 1% of patients during clinical trials of the medicine.


Q: What is the half-life of Reprexain, and why does that matter?

A: The mean plasma half-life of the hydrocodone component is about 4.5 hours, and the half-life of the ibuprofen component is about 2.2 hours. The half-life describes the time required for the body to eliminate half of the medicine's concentration. This information is a factor used by healthcare providers to determine appropriate dosing frequency.


Q: Is Reprexain considered habit-forming or addictive?

A: Because of its hydrocodone component, Reprexain has the potential to cause physical dependence and can be abused. Official regulatory documents outline that it may be misused in a way similar to other opioid medicines.


Q: Does Reprexain lose its effectiveness over time (tolerance)?

A: Regulatory documents state that patients may develop tolerance to the hydrocodone component over time. Tolerance is the clinical term used to describe a need for increased doses to achieve the same initial effect, or a noticeable reduction in the effect of the medicine.


Q: What is the difference between an allergy to Reprexain and a common side effect?

A: An allergy (hypersensitivity) to Reprexain or other similar drugs is a severe reaction that contraindicates (prohibits) its use and can involve symptoms like asthma or serious swelling. A common side effect, such as a headache or nausea, is a frequently reported reaction that does not typically prohibit the medicine's use.


Q: Does the efficacy of Reprexain change based on age or gender?

A: Official documents note that older patients (geriatric use) may be at an increased risk for serious side effects related to heart, kidney, or stomach issues, potentially requiring caution. However, regulatory studies have not demonstrated problems specific to the elderly that limit the drug's intended analgesic effect (efficacy).


Q: Can Reprexain be crushed or split for easier use?

A: Reprexain is manufactured as a conventional tablet designed for oral consumption. Official safety guidance notes that modifying the tablet could lead to the rapid release of the entire dose, significantly increasing the risk of an overdose. This safety principle is a key consideration for how the tablet should be administered.


Q: What are the typical signs of an adverse reaction to Reprexain?

A: Signs of serious adverse reactions include symptoms of heart problems, such as chest pain or shortness of breath. Other warnings relate to stomach bleeding, which may present as dark or bloody stools and severe stomach pain. Signs of severe opioid effects include profound sleepiness or very slow, shallow breathing.

How should Reprexain be stored and disposed of?

How to Store and Dispose of Reprexain

Reprexain (hydrocodone bitartrate and ibuprofen tablets) must be stored under specific environmental and security conditions and requires specialized disposal due to its opioid content.

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C. To maintain product stability, the tablets must be kept in a tight, light-resistant container. Due to the presence of hydrocodone, the medication must be stored in a secure location and kept out of the sight and reach of children to prevent accidental ingestion and abuse.

Disposal Instructions

Official regulatory guidance specifies that unused or expired Reprexain should be disposed of through a drug take-back program. If a take-back program is not immediately available, the unused medication is specifically recommended for immediate flushing down the toilet. This measure is required for certain opioid medicines to prevent serious harm or death from accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reprexain found in:

A-Z Index: